The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

Investorideas.com ( a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, ...

Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...

in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line ...

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.